Herbert Hurwitz
Expertise in
1
conditions

Dr. Herbert Hurwitz

Hematology | Oncology
Private Diagnostic Clinic PLLC
2100 Erwin Rd, 
Durham, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
Private Diagnostic Clinic PLLC
2100 Erwin Rd, 
Durham, NC 

Overview

Herbert Hurwitz is a Hematologist and an Oncologist in Durham, North Carolina. Dr. Hurwitz is highly rated in 1 condition, according to our data. His top areas of expertise are Agranulocytosis, Febrile Neutropenia, Gastroesophageal Junction Cancer, Pancreaticoduodenectomy, and Bone Marrow Transplant.

His clinical research consists of co-authoring 127 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in NC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Private Diagnostic Clinic PLLC
2100 Erwin Rd, Durham, NC 27705

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Enrollment Status: Recruiting
Publish Date: February 28, 2025
Intervention Type: Other
Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Cediranib maleate, Olaparib
Study Phase: Phase 2
A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers With Response and Resistance
A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers With Response and Resistance
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drug: Ibrutinib
Study Phase: Phase 2
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Radiation
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Drug
Study Drugs: Berzosertib, Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Other, Drug
Study Drug: Trametinib
Study Phase: Phase 2
BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer
BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: August 23, 2024
Intervention Type: Other, Drug, Biological
Study Phase: Phase 2
A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Navitoclax, Osimertinib
Study Phase: Phase 1
A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies
A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: February 10, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 DART® Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma
A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 DART® Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Trial of the IGF-1R Antibody AMG 479 in Combination With Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer (The RAP Trial)
A Phase I Trial of the IGF-1R Antibody AMG 479 in Combination With Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer (The RAP Trial)
Enrollment Status: Completed
Publish Date: August 28, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

127 Total Publications

Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants.
Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants.
Journal: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Published: May 03, 2024
Similar Doctors
Expertise in
32
conditions
Dr. Nigel Key
Hematology | Oncology
Expertise in
32
conditions
Dr. Nigel Key
Hematology | Oncology

UNC Hospitals Outpatient Center At Eastowne

100 Eastowne Dr, 
Chapel Hill, NC 
 (5.9 miles away)
984-974-2695
Languages Spoken:
English
See accepted insurances

Nigel Key is a Hematologist and an Oncologist in Chapel Hill, North Carolina. Dr. Key is highly rated in 32 conditions, according to our data. His top areas of expertise are Hemophilia B, Hemophilia A, Blood Clots, and Sickle Cell Disease.

Expertise in
17
conditions
Dr. David Ashley
Hematology | Oncology
Expertise in
17
conditions
Dr. David Ashley
Hematology | Oncology

Duke University Health System Inc

20 Duke Medicine Cir, 
Durham, NC 
 (0.3 miles away)
919-684-5301
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Ashley is a Hematologist and an Oncologist in Durham, North Carolina. Dr. Ashley is highly rated in 17 conditions, according to our data. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri.

Expertise in
4
conditions
Dr. Paul Monahan
Hematology | Oncology
Expertise in
4
conditions
Dr. Paul Monahan
Hematology | Oncology

UNC Hospitals Pulmonary Function Lab

101 Manning Dr, 
Chapel Hill, NC 
 (9.8 miles away)
919-966-4131
Languages Spoken:
English

Paul Monahan is a Hematologist and an Oncologist in Chapel Hill, North Carolina. Dr. Monahan is highly rated in 4 conditions, according to our data. His top areas of expertise are Hemophilia B, Blood Clots, Hemophilia A, and Hemophilic Arthropathy.

Frequently Asked Questions about Dr. Herbert Hurwitz

How do I make an appointment with Dr. Herbert Hurwitz?

You can book an appointment with Dr. Herbert Hurwitz by calling their office at 919-620-4467. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Herbert Hurwitz a top-rated expert for Agranulocytosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Herbert Hurwitz is classified as an Advanced expert for Agranulocytosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Herbert Hurwitz specialize in?

While Dr. Herbert Hurwitz is a Hematology, they have specific expertise in Agranulocytosis, Febrile Neutropenia, and Gastroesophageal Junction Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Herbert Hurwitz participate in research or clinical trials?

Yes. Dr. Herbert Hurwitz has published 127 articles and abstracts on conditions like Agranulocytosis. You can view a list of Dr. Herbert Hurwitz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hurwitz's expertise for a condition
ConditionClose
      View All 29 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile